echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Self-made hematopoietic stem cell gene therapy OTL-203 for the treatment of type I muscosal polysaccharides: fda-named orphan medicine and rare pediatric disease.

    Self-made hematopoietic stem cell gene therapy OTL-203 for the treatment of type I muscosal polysaccharides: fda-named orphan medicine and rare pediatric disease.

    • Last Update: 2020-07-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    It was announced that its in vitro hematopoietic stem cell () gene therapy-type mucosacized reservoir disorder () was awarded the title of Orphan Drug and the title of Rare Pediatric Disease by the U.S

    Food and Drug Administration

    Photo Source: A temporary data trial was recently announced to assess the safety and effectiveness of the experiment

    All eight patients treated reached the primary endpoint of the trial, and in the first two patients who followed at least one year, motor skills improved cognitive performance and normal growth compared to baseline levels

    About heterolyse polysaccharides () is a rare hereditary neurometabolic disease caused by the lack of alpha-aduaform acid asse () lysozyme () this enzyme needs to break down a sugar molecule called glycosamine polysaccharides (also known as glycosain)

    Accumulation in multiple organs can cause a variety of symptoms including neurocognitive impairment, bone deformities, vision and hearing loss, and cardiovascular and lung complications

    The overall estimated frequency of occurrence is one for each infant

    There are three seed types about % of children with the most severe subtype called syndrome without treatment rarely surviving

    Treatment options, including hematopoietic stem cell transplantation and chronic enzyme replacement therapy, have obvious limitations

    Although early intervention with enzyme replacement therapy has been shown to delay or prevent certain clinical features of the disease, the efficacy of neurological symptoms is limited

    An in vitro hematopoietic stem cell gene therapy is currently being studied and treated

    The exclusive worldwide license for intellectual property was developed by the Italian Institute of Gene Therapy

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.